The latest price target for Compass Therapeutics (NASDAQ:CMPX) was reported by Cantor Fitzgerald on December 3, 2025. The analyst firm set a price target for $0.00 expecting CMPX to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Compass Therapeutics (NASDAQ:CMPX) was provided by Cantor Fitzgerald, and Compass Therapeutics initiated their overweight rating.

The last upgrade for Compass Therapeutics Inc happened on April 2, 2025 when Leerink Partners raised their price target to $6. Leerink Partners previously had a market perform for Compass Therapeutics Inc.

There is no last downgrade for Compass Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compass Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compass Therapeutics was filed on December 3, 2025 so you should expect the next rating to be made available sometime around December 3, 2026.

While ratings are subjective and will change, the latest Compass Therapeutics (CMPX) rating was a initiated with a price target of $0.00 to $0.00. The current price Compass Therapeutics (CMPX) is trading at is $5.16, which is out of the analyst’s predicted range.